NCT05634720View on ClinicalTrials.gov

Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer

PHASE4Enrolling by invitationINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 2, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2028

Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
DRUG

HA Chemotherapy

Patients will receive the interventional treatment, which is neoadjuvant HA chemotherapy (FUDR/oxaliplatin delivered via the Hepatic Artery).

Trial Locations (1)

27710

Duke University Health System, Durham

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
lead

Duke University

OTHER

NCT05634720 - Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer | Biotech Hunter | Biotech Hunter